EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Burning Rock Biotech's Enterprise Value is $-21.98 Mil.
Burning Rock Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-19.95 Mil. Therefore, Burning Rock Biotech's EV-to-FCF for today is 1.10.
The historical rank and industry rank for Burning Rock Biotech's EV-to-FCF or its related term are showing as below:
LSE:BNR'
s EV-to-FCF Range Over the Past 10 Years
Min: -577.67 Med: -2.86 Max: 1.47
Current: 1.47
During the past 7 years, the highest EV-to-FCF of Burning Rock Biotech was 1.47. The lowest was -577.67. And the median was -2.86.
LSE:BNR's EV-to-FCF is ranked better than 91.4% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.12
vs LSE:BNR: 1.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Burning Rock Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Burning Rock Biotech's EV-to-FCF
For the Diagnostics & Research subindustry, Burning Rock Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's EV-to-FCF falls into.
Burning Rock Biotech's current Enterprise Value is $-21.98 Mil.
Burning Rock Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (LSE:BNR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Burning Rock Biotech's PE Ratio (TTM) for today is calculated as:
Burning Rock Biotech's share price for today is $3.562.
Burning Rock Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.655.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Burning Rock Biotech EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Burning Rock Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:BNR has been successfully added to your 